Home - Sysmex

Welcome to Sysmex Inostics

Empowering discoveries in oncology

We provide ultra-sensitive liquid biopsy solutions for exceptional ctDNA detection. We partner with BioPharma companies to aid cancer drug and diagnostic development to monitor therapy response, identify targetable resistance, and detect minimal residual disease (MRD).

Our Approach

No molecule left behind

We are devoted to ultra-sensitive and accurate detection of ctDNA from a simple blood draw. Focused and flexible genomic coverage can expedite oncology studies and provide deeper insights into patient response to new therapies. Our technology is optimized to ensure low-frequency mutant molecule detection with high specificity and efficiency.

Learn more about Sysmex Inostics

Approach

Our Products & Solutions

Sensitive and specific liquid biopsy

About Us

On a mission to help defeat cancer

We’re pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection. With more than 10 years of partnership experience with leading BioPharma companies, we offer expert-developed Plasma-Safe-SeqS (NGS) and OncoBEAM™ (digital PCR) technologies and cost-effective assays from our CLIA-certified lab.

News & Events

The latest

Visit our resource center

Press Release Feb. 22, 2022

Sysmex Inostics Introduces CLIA-Validated Highly Sensitive HNSCC-SEQ Testing Services for Head and Neck Cancer at the 2022 Molecular Medicine Tri-Conference

Presenting Poster of Clinical Trial Findings at 2022 Multidisciplinary Head and Neck Cancers Symposium Baltimore,…

Press Release Jan. 26, 2022

University of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients

Baltimore, MD, January 26, 2022 – Sysmex Inostics, a global leader in the liquid biopsy…

Press Release Oct. 20, 2021

New Ultra-Sensitive Leukemia Blood Test Delivered by Sysmex Inostics

Sysmex Inostics has developed a new CLIA-validated liquid biopsy test for the detection of Minimal…